Protease inhibitors
(Die Seite wurde neu angelegt: „ '''host proteases''' {{tp|p=32577236|t=2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.|pdf=|usr=011}} '''cathepsin L''' {{tp|p=32…“) |
|||
| Zeile 2: | Zeile 2: | ||
'''host proteases''' | '''host proteases''' | ||
{{tp|p=32577236|t=2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.|pdf=|usr=011}} | {{tp|p=32577236|t=2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.|pdf=|usr=011}} | ||
| + | {{tp|p=32537610|t=2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.|pdf=|usr=011}} | ||
'''cathepsin L''' | '''cathepsin L''' | ||
Version vom 8. Juli 2020, 14:05 Uhr
host proteases
32577236 2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.
32537610 2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.
cathepsin L
32470470 2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.
Camostat mesilate serine proteinase inh
32347443 ä. Camostat mesilate therapy for COVID-19
32489508 2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
Nafamostat mesilate serine proteinase inh
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32470602 2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.
| 32532094 2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. |
